Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDNO First-in-Human Study
NCT04891354Phase 1Completed
- Sponsor
- Attgeno AB
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of PDNO in pulmonary hypertension (PH) (2 arms), sponsored by Attgeno AB. Primary endpoint: Safety and tolerability of PDNO at Day 8. Started Feb 2021; status: completed.
02
Drugs
PDNO
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT04891354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891354.